TrialAntimicrobial agents and chemotherapy2015

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.

K L Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.